Demonstrate agility in responding to emerging competitor data and evolving evidence needs, including proactively monitor and assess the evolving clinical, competitive, payer, and evidence landscape for BRUKINSA and relevant hematologic malignancies, timely assessment of evidence gaps and development of HEOR/RWE analyses and evidence-generation strategies to support differentiation and value demonstration. Identify evidence gaps and opportunities, develop and execute integrated value evidence generation plan (including disease burden, treatment patterns, comparative effectiveness, indirect comparisons, economic modeling, and patient-centered outcomes) to strengthen differentiation and demonstrate clinical and economic value.